Discontinued — last reported Q3 '20
Investing
Acquired in-process research and development
Eli Lilly Acquired in-process research and development decreased by 10.9% to $584.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.8%, from $1.57B to $584.00M.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalContext dependent
VolatilityVolatile
First reportedQ3 2020
Last reportedQ3 2020
How to read this metric
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Detailed definition
This represents the cash outflow for the acquisition of in-process research and development projects from other entities...
Peer comparison
High in the pharmaceutical industry where external innovation is a primary driver of long-term revenue.
Metric ID:
acquired_ipr_dHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | $174.00M | $165.60M | $440.40M | $30.00M | $105.00M | $97.10M | $1.40B | $0.00 | $110.50M | $154.30M | $2.83B | $1.57B | $153.80M | $655.70M | $584.00M |
| QoQ Change | — | +596.0% | -4.8% | +165.9% | -93.2% | +250.0% | -7.5% | >999% | -100.0% | — | +39.6% | >999% | -44.4% | -90.2% | +326.3% | -10.9% |
| YoY Change | — | — | — | >999% | — | -36.6% | -78.0% | — | -100.0% | +5.2% | +58.9% | +101.6% | >999% | -0.3% | -76.8% | -62.8% |
Range$0.00 – $2.83B
CAGR+131.7%
Avg YoY Growth+254.1%
Median YoY Growth-0.3%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
| Total | $1.57B | $153.80M | $655.70M | — | $584.00M |
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Eli Lilly's acquired in-process research and development?
- Eli Lilly (LLY) reported acquired in-process research and development of $584.00M in Q1 2026.
- How has Eli Lilly's acquired in-process research and development changed year-over-year?
- Eli Lilly's acquired in-process research and development decreased by 62.8% year-over-year, from $1.57B to $584.00M.
- What does acquired in-process research and development mean?
- Cash spent to acquire research projects or drug candidates currently in development.